[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41

Advertisement
4. Takagi T, Saotome T: Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma; 2001 Aug;42(4):577-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
  • Irinotecan hydrochloride (CPT-11), a DNA topoisomerase-I inhibitor, is now widely used in the treatment of various solid tumors, including colorectal, gastric, breast, lung, and ovarian cancer.
  • Despite the good response shown in the late phase-II study, CPT-11 was not often employed in the treatment of malignant lymphoma, mainly because of severe leukopenia and diarrhea caused by the recommended schedule: 40 mg/m2 of CPT-11 on days 1 to 3, 8 to 10, 15 to 17, then discontinued for at least 2 weeks.
  • Subsequently, a lower dose schedule (less than 40 mg/m2) was developed.
  • Our phase II trial employing a reduced dose of CPT-11 on days 1 and 2, plus ADM on day 3 with 3-week interval in patients with refractory and relapsed NHL showed a fairly good response of relapsed B-cell lymphoma and a substantial response of T-cell lymphoma with acceptable toxicity.
  • The combination of a topoisomerase-I inhibitor (CPT-11) and a topoisomerase-II inhibitor is an interesting concept for the treatment of NHL.
  • Another phase II trial in combination with CPT-11 and other anti-cancer drugs, particularly cisplatin or topoisomerase-II inhibitors, is warranted.
  • A superior salvage chemotherapy regimen could be found in the future by investigating combinations of low-dose CPT-11 and cisplatin or topoisomerase-II inhibitors.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Salvage Therapy. Topoisomerase I Inhibitors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697485.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 42
  •  go-up   go-down


5. Rothenburger M, Semik M, Hoffmeier A, Baba H, Kamanabrou D, Roos N, Schmidt C, Scheld HH: Coexistence of non-Hodgkin's lymphoma and non-small cell lung carcinoma: diagnosis and treatment. Thorac Cardiovasc Surg; 2002 Feb;50(1):59-61
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of non-Hodgkin's lymphoma and non-small cell lung carcinoma: diagnosis and treatment.
  • Abstract. In this communication, we will present a very rare case of the coexistence of non-Hodgkin's lymphoma (NHL; low malignant lymphocytic lymphoma of the B-cell type) and a non-small-cell lung carcinoma (NSCLC).
  • A patient with a 15-year history of NHL developed a generalized relapse of the lymphoma with an additional tumor mass in the left lower lobe of the lung.
  • Due to non-responding chemotherapy on the lung tumor, the coexistence of a second malignancy was histologically proved in a second bronchoscopy.
  • Resection of the lung tumor with complex lobectomy and lymphadenectomy was performed.
  • After that, chemotherapy with four cycles of carboplatin supplemented with taxol was induced.
  • This is a very rare case of the coexistence of NHL and NSCLC; we will discuss the difficulty of diagnostic and treatment of both tumor diseases.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung. Lung Neoplasms. Lymphoma, Non-Hodgkin. Neoplasms, Second Primary
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoscopy. Carboplatin / administration & dosage. Humans. Male. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11847607.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Seki Y, Koike T, Yano M, Aoki S, Hiratsuka M, Fuse I, Aizawa Y: Bone marrow necrosis with dyspnea in a patient with malignant lymphoma and plasma levels of thrombomodulin, tumor necrosis factor-alpha, and D-dimer. Am J Hematol; 2002 Jul;70(3):250-3
MedlinePlus Health Information. consumer health - Breathing Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow necrosis with dyspnea in a patient with malignant lymphoma and plasma levels of thrombomodulin, tumor necrosis factor-alpha, and D-dimer.
  • Non-Hodgkin's lymphoma (peripheral T cell, unspecified, clinical stage IIIEA) was diagnosed in a 54-year-old male.
  • He was treated weekly with chemotherapy consisting of pirarubicin hydrochloride, cyclophosphamide, methotrexate, vincristine sulfate, etoposide, and prednisolone.
  • After 6 weeks of treatment in a state of partial remission, he exhibited sudden dyspnea, chest pain, fever, and drowsiness.
  • Bone marrow specimen showed the characteristic features of necrosis without any signs of the involvement of lymphoma cells.
  • This patient was diagnosed as having bone marrow necrosis (BMN) during the recovery phase of bone marrow with G-CSF treatment after chemotherapy for malignant lymphoma.
  • After conservative therapy, inhalation of oxygen and stopping the administration of G-CSF, all clinical symptoms subsided except that the elevation of LDH continued for 1 month.
  • Although dyspnea is a rare symptom of BMN, it is important to rule out in BMN during the recovery phase of bone marrow with G-CSF treatment after chemotherapy for malignant lymphoma.
  • Activated neutrophils in the small vessels of the lung by G-CSF and microthrombi, suggested by the elevation of D-dimer, may participate in the onset of dyspnea, which is a rare symptom of the onset of BMN.
  • [MeSH-major] Bone Marrow / pathology. Dyspnea / etiology. Fibrin Fibrinogen Degradation Products / analysis. Lymphoma, T-Cell / pathology. Thrombomodulin / blood. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / adverse effects. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Middle Aged. Necrosis. Neutrophils / pathology. Neutrophils / physiology

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • Genetic Alliance. consumer health - Dyspnea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12111773.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / Thrombomodulin; 0 / Tumor Necrosis Factor-alpha; 0 / fibrin fragment D; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


7. Shimatani H, Furukawa K, Ebihara Y, Serizawa H, Tsuboi M, Ogata A, Konaka C, Kato H: An early stage diffuse B-cell lymphoma within a visible site of bronchofiberscope accompanied by peripheral lung cancer. Diagn Ther Endosc; 2000;6(4):179-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An early stage diffuse B-cell lymphoma within a visible site of bronchofiberscope accompanied by peripheral lung cancer.
  • We report a case of non-Hodgkin's lymphoma found at the orifice of right B2 accompanied by peripheral lung cancer in a 66-year-old asymptomatic man.
  • Chest X-ray films showed a mass shadow in the left lower lung field.
  • Transbronchial lung biopsy of left S9 demonstrated squamous cell carcinoma.
  • The biopsy specimen from that site showed non-Hodgkin's lymphoma (diffuse B-cell type).
  • After left lower lobectomy, systemic chemotherapy was performed.
  • It is rare for malignant lymphoma to be recognized bronchofiberscopically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493536.001).
  • [ISSN] 1070-3608
  • [Journal-full-title] Diagnostic and therapeutic endoscopy
  • [ISO-abbreviation] Diagn Ther Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2362766
  •  go-up   go-down


8. Frohlich DE, Chen JL, Neuberg D, Kehoe KM, Van den Abbeele AD: When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy? J Nucl Med; 2000 Feb;41(2):269-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
  • The purpose of this study was to evaluate the prevalence and characterize the patterns of hilar uptake (HU) on 67Ga-citrate imaging after cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimens for non-Hodgkin's lymphoma (NHL), to differentiate hilar lymphoma (HL) from HU of benign etiology.
  • METHODS: A total of 930 studies (698 planar, 232 thoracic SPECT) was reviewed retrospectively in 100 NHL patients (29 low-grade, 60 intermediate-grade, and 11 high-grade) treated with CHOP and followed up longitudinally with serial gallium studies (planar: median, 7; range, 3-16 studies in 100 patients; SPECT: median, 1; range, 0-11 studies in 72 patients) over a median duration of 36 mo (range, 6-112 mo) from diagnosis.
  • Clinical outcome and size changes over time on correlative CT and/or radiographs were used to evaluate benign versus malignant changes within the hila.
  • The prevalence of HU and HL at various time points was as follows: baseline HU, 52% with HL 60%; mid-CHOP HU, 59% with HL2%; post-CHOP HU, 52% with HL6%; follow-up HU, 76% with HL 9%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Citrates. Gallium. Gallium Radioisotopes. Lung / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Predictive Value of Tests. Prednisone / administration & dosage. Retrospective Studies. Time Factors. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10688110.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Citrates; 0 / Gallium Radioisotopes; 27905-02-8 / gallium citrate; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CH46OC8YV4 / Gallium; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Palenzuela G, Bernard F, Gardiner Q, Mondain M: Malignant B cell non-Hodgkin's lymphoma of the larynx in children with Wiskott Aldrich syndrome. Int J Pediatr Otorhinolaryngol; 2003 Sep;67(9):989-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant B cell non-Hodgkin's lymphoma of the larynx in children with Wiskott Aldrich syndrome.
  • A 15 years old male with a primary diagnosis of Wiskott Aldrich syndrome presented a laryngeal B cell lymphoma associated with Epstein-Barr virus.
  • A chemotherapy and a radiotherapy were started in association with an endoscopic debulking of the tumor.
  • The child died of respiratory failure secondary to a lung infection.
  • The incidence of NHL (non-Hodgkin's lymphoma) of laryngeal origin in infants is extremely low and to our knowledge it has never been found in Wiskott Aldrich syndrome.
  • [MeSH-major] Laryngeal Neoplasms / etiology. Laryngeal Neoplasms / therapy. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / therapy. Wiskott-Aldrich Syndrome / complications
  • [MeSH-minor] Adolescent. Burkitt Lymphoma / etiology. Burkitt Lymphoma / therapy. Chemotherapy, Adjuvant. Herpesvirus 4, Human / isolation & purification. Humans. Laryngoscopy. Male. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Wiskott Aldrich syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12907055.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


10. Hsu PK, Hsu HS, Li AF, Wang LS, Huang BS, Huang MH, Hsu WH: Non-Hodgkin's lymphoma presenting as a large chest wall mass. Ann Thorac Surg; 2006 Apr;81(4):1214-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as a large chest wall mass.
  • BACKGROUND: Malignant lymphoma presenting as a solitary chest wall mass is not frequently seen.
  • The treatment for primary chest wall lymphoma remains unclear.
  • METHODS: From 1991 to 2004, of 157 patients with initial presentation of isolated chest wall mass, non-Hodgkin's lymphoma was diagnosed in 7 of them.
  • Four of these 7 patients had the chest wall lymphoma as the only site of disease.
  • The other 3 patients had other organ involvement including lung, bone, or liver.
  • The pathologic diagnoses were malignant lymphoma in 2 patients and diffuse large B-cell lymphoma in 5 patients.
  • Three patients with chest wall lymphoma as the only site of disease had tumor excision followed by adjuvant chemotherapy.
  • The other patient with chest wall lymphoma as the only site of disease, who had chemotherapy as the initial treatment, remained free of disease for 6 months after treatment.
  • The other 3 patients with other organ involvement who were managed with chemotherapy with or without radiotherapy died of disease after a mean survival of 20 months.
  • CONCLUSIONS: Malignant lymphoma presenting as a large chest wall mass is not common.
  • Although the primary treatment of choice for lymphoma with or without chest wall involvement is chemotherapy, surgery followed by adjuvant chemotherapy can provide satisfactory outcome for some patients in whom the chest wall lymphoma was the only site of disease.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse. Thoracic Neoplasms. Thoracic Wall

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Apr;81(4):1218-9 [16564246.001]
  • (PMID = 16564245.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 30
  •  go-up   go-down


11. Vera P, Ouvrier MJ, Hapdey S, Thillays M, Pesquet AS, Diologent B, Callonec F, Hitzel A, Edet-Sanson A, Ménard JF, Jardin F, Tilly H: Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging; 2007 Dec;34(12):1943-52
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?
  • PURPOSE: In patients with lymphoma, we investigated the impact of contrast-enhanced CT on PET attenuation correction in lesions and normal tissues, particularly when PET/CT was performed after chemotherapy.
  • METHODS: Fifty patients (51+/-18 years) with Hodgkin's disease (n=17) or non-Hodgkin lymphomas (n=33) were studied before and after chemotherapy.
  • HU(mean), SUV(max) and SUV(mean) were measured before and after chemotherapy in ten non-tumoural ROIs [aorta, femur, kidney, lung, iliopsoas muscle, occipital cortex, T12 vertebra, liver, spleen and inferior vena cava (IVC)] and in tumoural lymphadenopathies or malignant tissues (n=397 and 51 VOIs respectively before and after chemotherapy) using a 3D-thresholding method (identical threshold for PET- and PET+).
  • RESULTS: In the non-tumoural tissues, HU(mean) increased significantly in the CT+ compared with the CT- in the vessels and the highly vascularised organs, and slight increases were observed in the occipital cortex (+11%), the iliopsoas muscle (+6%) and the femur (+3%).
  • In the lesions, HU(mean) was not significantly different before and after chemotherapy, whatever the normal region considered.
  • SUV(max) increased significantly after treatment in the T12 vertebra (+12%).
  • SUV(mean) increased significantly after treatment in the T12 vertebra (+13%) and in the liver (+12%).
  • HU(mean) increased significantly in the CT+ compared with the CT- in the lesions (+55%) before chemotherapy.
  • SUV(max) and SUV(mean) increased significantly in the PET+ compared with the PET- in the lesions (+4%) only before chemotherapy.
  • No significant difference was seen in measurements (HU(mean), SUV(max) and SUV(mean)) after chemotherapy.
  • CONCLUSION: Our study demonstrates that use of enhanced CT for attenuation correction has a negligible effect on quantification at staging and after chemotherapy.
  • A "single-shot" enhanced PET/CT may thus be performed in the evaluation of patients with lymphoma at staging, during treatment and at follow-up.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Contrast Media. Lymphoma / diagnostic imaging. Lymphoma / drug therapy. Positron-Emission Tomography / methods. Subtraction Technique. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1167-75 [15909196.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):W498-502 [17056880.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):922-7 [12111133.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1129-36 [12215549.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Clin Nucl Med. 2000 Nov;25(11):905-10 [11079589.001]
  • [Cites] J Nucl Med. 2005 Mar;46(3):429-35 [15750155.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):325-9 [14647988.001]
  • [Cites] Q J Nucl Med. 2002 Mar;46(1):24-34 [12072843.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):983-95 [15937310.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1326-34 [16883013.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10 ):1643-8 [17015900.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):308-19 [16423932.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1555-60 [12438054.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2505-9 [9406703.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] J Nucl Med. 2004 May;45(5):784-8 [15136627.001]
  • [Cites] Br J Radiol. 2004 Aug;77(920):662-5 [15326044.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):470-6 [16513616.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):22-8 [14574514.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):283-91 [15695788.001]
  • [Cites] Radiology. 2002 Nov;225(2):575-81 [12409597.001]
  • [Cites] Radiology. 2003 Jun;227(3):817-24 [12773683.001]
  • (PMID = 17694309.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  •  go-up   go-down


12. Li L, Su LP, Ma L, Zhao J, Zhu L, Zhou YA: [Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):199-202
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma].
  • OBJECTIVE: To explore the expression and clinical significance of P-glycoprotein (P-gp)/mdr1mRNA, multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in newly diagnosed non-Hodgkin's lymphoma.
  • METHODS: mdr1 mRNA of in 41 patients with non-Hodgkin's lymphoma was assayed by semi-quantitative RT-PCR.
  • No correlation was showed among the expressions of P-gp, MRP and LRP. (3) Patients with P-gp expression had a poorer outcome of chemotherapy than those with P-gp-negative (P = 0.005).
  • P-gp expression was significantly associated with higher clinical stage (P = 0.046) and elevated serum lactate dehydrogenase level (P = 0.032), but not associated with malignant degree (P = 0.298).
  • MRP had no impact on the outcome of chemotherapy (P = 0.212), and wasn't significantly associated with higher clinical stage (P = 0.369), elevated LDH (P = 0.762) and higher malignant degree (P = 0.451).
  • Patients with LRP expression had a poorer outcome of chemotherapy than those LRP-negative (P = 0.012).
  • LRP expression was significantly associated with higher clinical stage (P = 0.0019), elevated LDH (P = 0.02) and higher malignant degree (P = 0.01).
  • CONCLUSION: The data of this study indicate that P-gp and LRP expressions but not MRP expression are important in the mechanism of drug resistance associated with a poor clinical outcome in previously untreated NHL.
  • [MeSH-major] Drug Resistance, Multiple. Lymphoma, Non-Hodgkin / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Child. Drug Resistance, Neoplasm. Female. Humans. Lactate Dehydrogenases / blood. Lymph Nodes / metabolism. Male. Middle Aged. Neoplasm Staging. P-Glycoproteins. RNA, Messenger / metabolism. Remission Induction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615260.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 1.1.- / Lactate Dehydrogenases
  •  go-up   go-down


13. Dorenbeck U, Hollerbach S, Geissler A, Andus T: [Pulmonary metastasis of extranodal high malignancy B-cell non-Hodgkin lymphoma of the bulbus duodeni and pylorus of the stomach]. Z Gastroenterol; 2000 Feb;38(2):173-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastasis of extranodal high malignancy B-cell non-Hodgkin lymphoma of the bulbus duodeni and pylorus of the stomach].
  • [Transliterated title] Pulmonale Metastasierung eines extranodalen hochmalignen B-Zell-Non-Hodgkin-Lymphoms des Bulbus duodeni und Pylorus des Magens.
  • Chest X-ray showed two masses, 2 cm and 3 cm in diameter, in the left and right lower lung.
  • Biopsy proved a high malignant B-cell non-Hodgkin's lymphoma of the stomach.
  • The masses in the lung were identified as metastases of the gastrointestinal lymphoma.
  • In conclusion on this tumor was an extranodal non-Hodgkin's lymphoma stadium BE IV according to Musshoff.
  • A CHOP-chemotherapy was initiated.
  • Primary gastrointestinal non-Hodgkin's lymphomas are relatively rare neoplasms of the abdomen.
  • Unusual and interesting in this case ist the metastatic pattern involving the lung periphery without local lymph node metastases.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphoma, B-Cell / diagnosis. Pyloric Antrum. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Duodenum / pathology. Female. Gastroscopy. Humans. Tomography, X-Ray Computed


14. Yamane T, Daimaru O, Ito S, Nagata T, Yoshiya K, Fukaya N, Ito S, Imai T, Uchida H: Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. Ann Nucl Med; 2008 Oct;22(8):719-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.
  • Drug-induced pneumonitis is a serious and an unpredictable side effect of chemotherapy in patients with malignant lymphoma.
  • We present the case of a 51-year-old man who developed drug-induced pneumonitis during chemotherapy for non-Hodgkin's lymphoma in which pneumonitis was detected earlier by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) than by high-resolution computed tomography (HRCT).
  • After five courses of chemotherapy, 18F-FDG-PET was performed for assessing residual lesions, and diffuse lung uptake was incidentally observed.
  • Drug-induced pneumonitis was finally diagnosed, and treatment was initiated.
  • 18F-FDG-PET can be an imaging modality for detecting drug-induced pneumonitis at an extremely early stage in which HRCT is incapable of revealing any abnormal changes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / diagnosis. Pneumonia / chemically induced. Pneumonia / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Humans. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Radiopharmaceuticals. Sensitivity and Specificity. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982476.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


15. O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL: A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res; 2000 Sep-Oct;20(5C):3647-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
  • BACKGROUND: Prior clinical trials proved that all histologic grades of chemotherapy-resistant B-cell non-Hodgkin's lymphoma (NHL) could respond to radio-immunotherapy (RIT) with 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1.
  • METHODS: Lym-1 is a mouse monoclonal antibody that preferentially targets malignant B-lymphocytes.
  • 90Y has beta emissions suitable for therapy but no gamma emissions, therefore, 111In-2IT-BAD-Lym-1 is used for imaging.
  • The macrocyclic chelator, DOTA, bound 90Y tightly to form a stable drug.
  • Patients with chemotherapy-resistant NHL received 90Y-2IT-BAD-Lym-1 at administered doses of: 0.185, 0.278, or 0.370 GBq/m2.
  • No significant non-hematologic toxicity occurred.
  • Human anti-mouse antibody (HAMA) developed in 3/8 patients.
  • The mean radiation dose to the 33 imaged tumors was 7.0 Gy/GBq.
  • Lung, kidney and liver received mean radiation doses of 1.3, 2.4, and 6.4 Gy/GBq, respectively from 90Y-2IT-BAD-Lym-1.
  • In this Phase I study, 5/8 patients that failed prior chemotherapy had a partial response or stabilization of NHL after RIT.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / adverse effects. Yttrium Radioisotopes / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268433.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA47829
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 2IT-BAD-Lym-1 monoclonal antibody; 0 / Antibodies, Heterophile; 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes
  •  go-up   go-down


16. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data.
  • Second neoplasm developed in 32 cases (4.8%).
  • Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia.
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Renno SI, Moreland WS, Pettenati MJ, Beaty MW, Keung YK: Primary malignant lymphoma of uterine corpus: case report and review of the literature. Ann Hematol; 2002 Jan;81(1):44-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of uterine corpus: case report and review of the literature.
  • We describe a patient presenting with postmenopausal vaginal bleeding and a uterine mass subjected to endometrial biopsy that showed a high-grade non-Hodgkin's lymphoma, consistent with a diffuse large B-cell lymphoma.
  • Staging computed tomography (CT) scans of the chest, abdomen, and pelvis revealed three lung nodules in addition to the uterine mass.
  • Fine needle aspirate of one lung lesion showed lymphomatous involvement.
  • She was treated with intensive chemotherapy alone and has remained in complete remission 21 months after diagnosis.
  • The literature on primary lymphoma of the uterine corpus is reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms. Lymphoma, Large B-Cell, Diffuse. Uterine Neoplasms


18. Kataoka T, Ishida Y, Kurokawa R, Takeshita S, Ohta K, Nishimura Y, Yokoyama M: [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab]. Nihon Kokyuki Gakkai Zasshi; 2003 Dec;41(12):899-904
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
  • Histopathological examination of the inguinal lymph nodes revealed follicular B-cell non-Hodgkin's lymphoma (NHL).
  • In spite of 9 cycles of chemotherapy (CHOP/COP), progression of the disease was seen.
  • Fever and dyspnea developed.
  • Transbronchial biopsy revealed pulmonary involvement of diffuse B-cell lymphoma.
  • Salvage chemotherapy (ESHAP, EPOCH) was not effective.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14727553.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


19. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • A B-cell non-Hodgkin's lymphoma (NHL) was diagnosed from biopsies of the stomach and liver.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / complications. Lymphoma, B-Cell / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Corn BW: Advances in the combination of radiation therapy and chemotherapy against cancer. Drug News Perspect; 2004 Dec;17(10):705-12
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the combination of radiation therapy and chemotherapy against cancer.
  • October 3-7, 2004, the American Society for Therapeutic Radiology and Oncology held its 46th Annual Meeting in Atlanta, Georgia, U.S.A.
  • The meeting was devoted to the presentation of advances in management of malignant diseases with radiation modalities.
  • The educational elements of this program are targeted at oncologists of all disciplines (i.e., surgical oncologists, medical oncologists, radiation oncologists), physicists, biologists, nurses, therapists and all health care workers who are involved in the treatment of patients with malignant diseases.
  • The program included presentations on standard, investigational and experimental therapeutics as well as intensity-modulated radiation therapy, treatment planning, alternative fractionation and molecular and radiation biology.
  • Specific clinical areas included gastrointestinal, breast, head and neck, central nervous system, pelvic and lung cancers.
  • Data on lymphomas (Hodgkin's disease and non-Hodgkin's lymphoma) were also presented.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Congresses as Topic. Female. Georgia. Humans. Male. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696234.001).
  • [ISSN] 0214-0934
  • [Journal-full-title] Drug news & perspectives
  • [ISO-abbreviation] Drug News Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Zhang LB, Sun YE, Yu CH, Liu Y: [Clinical diagnosis and surgical treatment of primary pulmonary lymphoma]. Zhonghua Wai Ke Za Zhi; 2006 Jan 15;44(2):97-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis and surgical treatment of primary pulmonary lymphoma].
  • OBJECTIVE: To study the clinical characteristics, the principles of diagnosis and surgical treatment for primary pulmonary lymphoma.
  • METHOD: Ten patients with primary pulmonary lymphoma were treated surgically and their clinical characteristics, the experiences of clinical diagnosis and surgical treatment were analyzed.
  • Only 2 cases were diagnosed as primary pulmonary lymphoma by percutaneous needle biopsy and pathologic examination.
  • All cases with non-Hodgkin's lymphoma received regular chemotherapy (MOPP and ABVD scheme for 1 case with Hodgkin's disease respectively, CHOP for 8 cases with non-Hodgkin's lymphoma), and 3 cases received radiotherapy postoperatively.
  • RESULTS: Eight cases were non-Hodgkin's lymphoma (B-type) and 2 cases were Hodgkin's disease (mixed type) confirmed by pathological examination.
  • Six cases with non-Hodgkin's lymphoma (3 cases for stage IE, 2 cases for stage II 1E, and 1 case for stage II 2E W) had been surviving for 18-42 months until the follow-up.
  • Two cases with non-Hodgkin's lymphoma (stage II 2E, B-cell, low-grade) and 2 cases with Hodgkin's disease (stage IE and II 2E, mixed type) died in 24, 32, 8 and 17 months postoperatively respectively.
  • CONCLUSIONS: Primary pulmonary lymphoma is a rare type of malignant lung neoplasm without special clinical features.
  • The preoperative diagnosis is difficult.
  • Treatment modalities include surgical treatment, radiotherapy and regular chemotherapy postoperatively.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Lymphoma / diagnosis. Lymphoma / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Pneumonectomy / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620666.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Goh SG, Chuah KL, Tan PH: Intravascular lymphomatosis of the lung and liver following eyelid lymphoma in a Chinese man and review of primary pulmonary intravascular lymphomatosis. Pathology; 2002 Feb;34(1):82-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular lymphomatosis of the lung and liver following eyelid lymphoma in a Chinese man and review of primary pulmonary intravascular lymphomatosis.
  • Intravascular lymphomatosis (IVL) is characterised by an almost exclusive intravascular proliferation of malignant lymphoid cells, with the diagnosis often made only when the illness is in its terminal phase or at autopsy.
  • We detail a case of IVL affecting the lung and liver of a 49-year-old Chinese man presenting primarily with lung symptoms and incidental findings of abnormal serum transaminase levels, the ante-mortem diagnosis being established on transbronchial lung biopsy and percutaneous liver biopsy specimens, respectively.
  • Histology disclosed CD20 + CD5 - CD10 [corrected] - malignant large mononuclear B cells within the lumina of the blood vessels of the affected organs as well as sinusoids of the liver.
  • Significantly, the patient had a history of large B cell lymphoma affecting the eyelid 18 months prior to the angiotropic disease, suggesting a possible link between the more common types of non-Hodgkin's lymphoma and IVL.
  • [MeSH-major] Eyelid Neoplasms / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Lymphoma, B-Cell / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Alanine Transaminase / blood. Antigens, CD / analysis. Aspartate Aminotransferases / blood. B-Lymphocytes / chemistry. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Combined Modality Therapy. Drug Therapy, Combination. Humans. Immunohistochemistry. Male. Middle Aged. Radiotherapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathology 2002 Jun;34(3):301
  • (PMID = 11902454.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


23. von der Weid NX: Adult life after surviving lymphoma in childhood. Support Care Cancer; 2008 Apr;16(4):339-45
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult life after surviving lymphoma in childhood.
  • INTRODUCTION: Almost all pediatric lymphomas are malignant, high-grade tumors.
  • The combined incidence of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) reaches 10 to 12 new cases a year per million children under the age of 16 years, representing about 10% of all pediatric cancers.
  • Intrathecal or high-dose intravenous chemotherapy with methotrexate may induce the same problems, although in a lesser extent and severity.
  • Large enough prospective cohort studies like the CCSS in the USA were able to show an increased risk of second malignant neoplasms, especially brain tumors in patients formerly treated with cranial irradiation.
  • Radiation therapy to the neck and mediastinum (mantle field) induces a 50% risk of developing hypothyroidism and a 20% risk of developing thyroid nodules at 20 years.
  • The risk of thyroid cancer is 18 times higher the expected rate for the general population.
  • Cardiac toxicity can be enhanced by the concomitant therapy with adriamycin and lung toxicity by bleomycin.
  • Radiotherapy to the paraaortic and iliacal lymph nodes can affect gonadal function both in males and females; concomitant chemotherapy with alkylating agents like cyclophosphamide and especially procarbazine have a synergistic action and can lead to premature menopause as well as infertility.
  • Although the vast majority of survivors from pediatric lymphomas fare well, a minority present with extreme symptoms of depression and psychosomatic distress; female sex, low socio-economic status and treatment with intensive chemotherapy are important risk factors for a poor psychosocial outcome.
  • A well functioning network of pediatric oncologists, GP's, adult oncologists and other specialists of adult medicine must be developed in order to prevent, early detect and treat expected long-term toxicities.
  • [MeSH-major] Lymphoma. Radiotherapy / adverse effects. Survivors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):28-36 [15654275.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4091-5 [11051261.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Cancer. 1981 May 15;47(10):2368-74 [6791800.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):571-7 [6547167.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2435-43 [10856104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80 [2211255.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] JAMA. 1979 Oct 26;242(17):1877-81 [480620.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • (PMID = 18196290.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


24. Koukourakis G, Kouloulias V: Lymphoma of the testis as primary location: tumour review. Clin Transl Oncol; 2010 May;12(5):321-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the testis as primary location: tumour review.
  • Non-Hodgkin's lymphoma as a primary testicular neoplasm accounts approximately 9% of all testicular malignant tumours and about 1-2% of all non-Hodgkin's lymphoma.
  • This neoplasm is the most common malignant tumour of the testis in the elderly.
  • The most common histotype in primary forms is the diffuse large B-cell lymphoma, whereas more aggressive histologies such as Burkitt's lymphoma are principal founded in cases of secondary involvement of the testis.
  • Despite the fact that responses to doxorubicin- containing chemotherapy, especially in early stages, show good results, relapses are often seen, and the prognosis of this tumour is very poor.
  • Testicular lymphoma often disseminates to other extranodal organs, such as contralateral testis, central nervous system (CNS), lung, pleura, Waldeyer's ring and soft tissue.
  • For patients with limited disease, the recommended first-line treatment is orchiectomy followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination chemotherapy, with central nervous system (CNS) prophylaxis and prophylactic irradiation of the contralateral testis.
  • In more advanced or relapsed disease, management should follow the worldwide recommendations for nodal diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):40-6 [11707869.001]
  • [Cites] Br J Urol. 1974 Oct;46(5):569-75 [4420636.001]
  • [Cites] Neth J Med. 1991 Aug;39(1-2):92-100 [1961354.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76 [543449.001]
  • [Cites] Am J Med. 1986 Sep;81(3):515-24 [3529957.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):197-204 [11773170.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Neurol Med Chir (Tokyo). 1986 Jan;26(1):68-70 [2425280.001]
  • [Cites] Oncology. 2000 May;58(4):286-92 [10838493.001]
  • [Cites] J Urol. 1969 Aug;102(2):230-2 [4895868.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1578-84 [6989476.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • [Cites] Clin Lymphoma. 2001 Sep;2(2):109-15 [11707851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):652-6 [11849786.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Clin Lymphoma. 2002 Dec;3(3):167-72 [12521394.001]
  • [Cites] Australas Radiol. 1991 Aug;35(3):257-60 [1763988.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):383 [2261381.001]
  • [Cites] J Urol. 1977 Nov;118(5):783-6 [916101.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):73-7 [7819053.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1361-7 [7751880.001]
  • [Cites] Eur Urol. 2000 Dec;38(6):774-7 [11111200.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] J Urol. 1994 May;151(5):1162-70 [8158751.001]
  • [Cites] J Urol. 1996 Mar;155(3):943-6 [8583613.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):99-106 [8356234.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] J Pak Med Assoc. 1994 Apr;44(4):86-8 [8072129.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1182-6 [7850719.001]
  • [Cites] J Urol. 1977 Dec;118(6):1004-7 [336911.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1093-9 [15754007.001]
  • [Cites] Nouv Rev Fr Hematol. 1995;37(5):267-72 [8700650.001]
  • [Cites] Oncology (Williston Park). 1998 Feb;12(2):185-91; discussion 192-5 [9507520.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Acta Oncol. 2004;43(8):758-65 [15764222.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • (PMID = 20466616.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 44
  •  go-up   go-down


25. Kelleher FC, McDermott R: The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer; 2010 Sep;46(13):2357-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
  • The anaplastic lymphoma kinase gene (ALK) is a gene on chromosome 2p23 that has expression restricted to the brain, testis and small intestine but is not expressed in normal lymphoid tissue.
  • It has similarity to the insulin receptor subfamily of kinases and is emerging as having increased pathologic and potential therapeutic importance in malignant disease.
  • This gene was originally established as being implicated in the pathogenesis of rare diseases including inflammatory myofibroblastic tumour (IMT) and ALK-positive anaplastic large cell lymphoma, which is a subtype of non-Hodgkin's lymphoma.
  • In 2007, an inversion of chromosome 2 involving ALK and a fusion partner gene in a subset of non-small cell lung cancer was discovered.
  • This has been described in ALK-positive anaplastic large cell lymphoma in which ALK is fused to NPM (nucleolar protein gene) and in non-small cell lung cancer where ALK is fused to EML4 (Echinoderm microtubule-associated protein 4).
  • Therapeutic targeting of ALK fusion genes using tyrosine kinase inhibition, vaccination using an ALK specific antigen and treatment using viral vectors for RNAi are emerging potential therapeutic possibilities.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / therapy. Drug Synergism. Gene Amplification. Humans. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / therapy. Mutation / genetics. Neuroblastoma / genetics. Neuroblastoma / therapy. Pyrimidines / therapeutic use. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases. Receptor, IGF Type 1 / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20451371.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GSK 1838705A; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


26. Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K: Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol; 2002 Oct 15;20(20):4255-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyothorax-associated lymphoma: a review of 106 cases.
  • PURPOSE: Pyothorax-associated lymphoma (PAL) is a non-Hodgkin's lymphoma developing in the pleural cavity after a long-standing history of pyothorax.
  • All patients had a 20- to 64-year (median, 37-year) history of pyothorax resulting from artificial pneumothorax for treatment of pulmonary tuberculosis (80%) or tuberculous pleuritis (17%).
  • Laboratory data showed that the serum neuron-specific enolase level was occasionally elevated (3.55 to 168.7 ng/mL; median, 18.65 ng/mL), suggesting a possible diagnosis of small-cell lung cancer.
  • Histologically, PAL usually showed a diffuse proliferation of large cells of B-cell type (88%).
  • PAL was responsive to chemotherapy, but the overall prognosis was poor, with a 5-year survival of 21.6%.
  • PAL is a non-Hodgkin's lymphoma of exclusively B-cell phenotype in the pleural cavity of patients with long-standing history of pyothorax, and is strongly associated with EBV infection.
  • Development of PAL is closely related to antecedent chronic inflammatory condition; therefore, PAL should be defined as malignant lymphoma developing in chronic inflammation.
  • [MeSH-major] Empyema, Pleural / complications. Lymphoma, Non-Hodgkin / etiology. Pleural Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377970.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE: Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma; 2001 Nov-Dec;42(6):1329-37
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis.
  • Infusion related adverse events (AE) with day 1 rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL) are common.
  • The purpose of this study was to evaluate the AE occurring in patients with malignant B-cell lymphocytosis who received rituximab.
  • The AE occurring on the day of rituximab, the treatment provided (including hospitalization), and the subsequent ALC responses were recorded.
  • A second patient developed a pulmonary syndrome five days after day 1 rituximab and required mechanical ventilation, but had no long-term lung toxicity.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphocytosis / drug therapy. Lymphoma, Mantle-Cell / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911416.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


28. Albuquerque MA, Migliari DA, Sugaya NN, Kuroishi M, Capuano AC, Sousa SO, Cavalcanti MG: Adult T-cell leukemia/lymphoma with predominant bone involvement, initially diagnosed by its oral manifestation: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Sep;100(3):315-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma with predominant bone involvement, initially diagnosed by its oral manifestation: a case report.
  • Adult T-cell leukemia/lymphoma (ATL/L) is a rare malignant neoplasm linked to human T-cell lymphotropic virus type 1 (HTLV-1).
  • We report a case of ATL/L (lymphoma-type) affecting a 30-year-old Brazilian woman.
  • Conventional radiographs and computed tomography revealed the involvement of several bones plus the lung and axillary lymph nodes.
  • Histopathological and immunohistochemical analyses of oral biopsy confirmed a T-cell non-Hodgkin's lymphoma.
  • Final diagnosis of ATL/L was made based on HTLV-1 positivity.
  • She underwent multiple cycles of chemotherapy, which produced some improvement, but she died as a consequence of pulmonary and hepatic complications 4 months after the initial diagnosis.
  • Besides the process of diagnosing and typing a malignant lymphoma, this article outlines the value of computed tomography and the necessity of performing HTVL-1 investigation in patients with a diagnosis of lymphoma of T-cell lineage.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / pathology. Palatal Neoplasms / etiology
  • [MeSH-minor] Adult. Antigens, CD45 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brazil. Fatal Outcome. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Immunohistochemistry. Protein Tyrosine Phosphatase, Non-Receptor Type 1. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122659.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 1
  •  go-up   go-down


29. Sun XF, Han B, Feng J, Zhou DB, Wang SJ, Xu Y, Chen JL, Jiao L, Zhang W, Li J, Duan MH, Zhu TN, Zou N, Hua BL, Cai HC, Zhao YQ: [Clinical features of invasive pulmonary fungal infection secondary to malignant blood diseases]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct;31(5):575-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of invasive pulmonary fungal infection secondary to malignant blood diseases].
  • OBJECTIVE: To summarize the clinical features of invasive pulmonary fungal infection (IPFI) secondary to malignant blood diseases (MBD).
  • RESULTS: The incidences of IPFI secondary to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and aplastic anemia (AA) were 4.6%, 3.2%, 2.8%, and 2.5%, respectively.
  • In patients with IPFI secondary to AML, 88.5% (23/26) of the patients suffered from the infections during the non-remission (NR) period (including relapse), and 11.5% (3/26) in the complete-remission (CR) period.
  • In all the patients with IPFI secondary to malignant blood diseases, 86.5% (45/52) of MBD were neutropenic or agranulocytic, and 67.3% (35/52) had been treated with broad-spectrum antibiotics for more than 96 hours before anti-fungal therapy.
  • The total mortality after anti-fungal therapy was 13.7% (7/51).
  • More than half of patients with fluconazole or itraconazole as the first-line therapy had to switch to other medicines because of poor infection control.
  • [MeSH-major] Hematologic Neoplasms / complications. Lung Diseases, Fungal / diagnosis. Lung Diseases, Fungal / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968074.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E: Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol; 2002 Aug;25(4):371-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia in oncology practice: relation to diseases and their therapies.
  • Anemia is common in patients with cancer and is a frequent complication of myelosuppressive chemotherapy.
  • In this study, we investigated the incidence and severity of chemotherapy-induced anemia caused by the most common chemotherapy regimens, including the new generation of chemotherapeutic agents, used in the treatment of the major nonmyeloid malignancies in adults.
  • Five hundred fifty-two patients with histologically proven carcinoma originating from breast (n = 165), lung (n = 128), colon (n = 75), ovary (n = 84), and malignant lymphoma (n = 100) were included in this study.
  • Hemoglobin levels for each patient were measured with an automatic counter during both pretreatment and before each chemotherapy cycle during therapy.
  • Before chemotherapy, 44% of patients with breast carcinoma had anemia.
  • There was a 16% increase in the incidence of anemia after chemotherapy.
  • However, single-agent chemotherapy with newer generation caused more anemia when compared with the FAC regimen (p < 0.005).
  • Chemotherapy resulted in a significant decrease in hemoglobin levels when compared with pretreatment values in patients with lung cancer (p < 0.001).
  • During treatment, the increase in the incidence of grade II anemia was associated with a parallel decrease in the incidence of grade I anemia.
  • The incidence of anemia was equivalent in both patients with small-cell lung cancer and those with non-small-cell lung cancer treated with the etoposide and cisplatin (EP) combination.
  • Seventy-one percent of patients with colon cancer had anemia before initiation of chemotherapy.
  • Chemotherapy resulted in a prominent increase in incidence of anemia, which increased to 91.5%.
  • Less than 10% of patients developed severe anemia.
  • Showing a high incidence of anemia (82%) at presentation, hemoglobin levels in patients with malignant lymphoma were unaltered with chemotherapy.
  • There was a higher incidence of anemia in patients with non-Hodgkin's lymphoma receiving the cyclophosphamide, epirubicin, vincristine, prednisone (CEOP) regimen in contrast to patients with Hodgkin's lymphoma treated with the doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) combination.
  • In this study, we have observed equivalent rates of treatment-related anemia when compared with previous data in patients with specific tumor types.
  • The mechanisms underlying the propensity for a higher risk of pretreatment anemia in patients with malignant disorders and its influence on the outcome has to be elucidated by further population-based and molecular studies.
  • [MeSH-major] Anemia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Colonic Neoplasms / drug therapy. Female. Humans. Incidence. Lung Neoplasms / drug therapy. Lymphoma / drug therapy. Male. Middle Aged. Ovarian Neoplasms / drug therapy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12151968.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Frankel SR: Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol; 2003 Apr;30(2):300-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
  • The components of the apoptotic pathway are targets for anticancer therapy.
  • Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies.
  • Randomized clinical trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), malignant melanoma, and non-small cell lung cancer.
  • In addition, nonrandomized trials are underway to evaluate oblimersen in non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and hormone-refractory prostate cancer.
  • Preclinical data support the clinical evaluation of oblimersen in additional tumor types, including chronic myelogenous leukemia, and breast, small cell lung, gastric, colon, bladder (CML), and Merkel cell cancers.
  • Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clinical trials will test this therapeutic approach.
  • [MeSH-major] Apoptosis. Down-Regulation / drug effects. Genes, bcl-2 / genetics. Oligonucleotides, Antisense / therapeutic use. Thionucleotides / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12720157.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Thionucleotides; 85J5ZP6YSL / oblimersen
  • [Number-of-references] 45
  •  go-up   go-down


34. Klasa RJ, Gillum AM, Klem RE, Frankel SR: Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev; 2002 Jun;12(3):193-213
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
  • The components of the apoptotic program are targets for anticancer therapy.
  • Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies (mAb).
  • Randomized clinical trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia, multiple myeloma, malignant melanoma, and non-small cell lung cancer.
  • In addition, nonrandomized trials are under way to evaluate oblimersen in non-Hodgkin's lymphoma, acute myeloid leukemia, and hormone-refractory prostate cancer.
  • Preclinical data also support the clinical evaluation of oblimersen in additional tumor types, including chronic myelogenous leukemia and breast, small cell lung, gastric, colon, bladder, and Merkel cell cancers.
  • Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clinical trials will test this therapeutic approach.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12162702.001).
  • [ISSN] 1087-2906
  • [Journal-full-title] Antisense & nucleic acid drug development
  • [ISO-abbreviation] Antisense Nucleic Acid Drug Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  • [Number-of-references] 124
  •  go-up   go-down


35. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M: Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol; 2009 Apr 1;27(10):1660-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To establish the maximum-tolerated dose and evaluate tolerability, pharmacokinetics, pharmacodynamic effects, and antitumor activity of AEG35156, a second-generation antisense to X-linked inhibitor of apoptosis (XIAP) protein, in patients with advanced refractory malignant tumors.
  • AEG35156 was administered by continuous intravenous infusion over 7 days (7DI) or 3 days (3DI) of a 21-day treatment cycle.
  • Suppression of XIAP mRNA levels was maximal at 72 hours (mean suppression, 21%), and this coincided with a dramatic decrease in circulating tumor cells in a patient with non-Hodgkin's lymphoma.
  • Circulating biomarkers of cell death and apoptosis altered in association with drug infusion and toxicity.
  • CONCLUSION: In this first-in-man study, AEG35156 was well tolerated, with predictable toxicities, pharmacokinetic properties, and clinical evidence of antitumor activity in patients with refractory lymphoma, melanoma, and breast cancer.
  • Phase I/II trials of AEG35156 chemotherapy combinations are ongoing in patients with pancreatic, breast, non-small-cell lung cancer, acute myeloid leukemia, lymphoma, and solid tumors for which docetaxel is indicated.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Neoplasms / drug therapy. Oligonucleotides / administration & dosage. Oligonucleotides, Antisense / administration & dosage. Oligonucleotides, Antisense / pharmacokinetics
  • [MeSH-minor] Female. Gene Expression / drug effects. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. X-Linked Inhibitor of Apoptosis Protein / drug effects. X-Linked Inhibitor of Apoptosis Protein / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19237630.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C237/A7819; United Kingdom / Cancer Research UK / / C96/A4743
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AEG 35156; 0 / Antineoplastic Agents; 0 / Oligonucleotides; 0 / Oligonucleotides, Antisense; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


36. Eklund JW, Kuzel TM: Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther; 2005 Feb;5(1):33-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Denileukin diftitox (DAB389IL-2; Ontak) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma.
  • It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells.
  • This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Clinical Trials as Topic. Graft vs Host Disease / drug therapy. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Psoriasis / drug therapy. Recombinant Fusion Proteins / therapeutic use. Survival

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757436.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Number-of-references] 26
  •  go-up   go-down


37. Reske SN, Kotzerke J: FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med; 2001 Nov;28(11):1707-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positron emission tomography (PET) is the most powerful molecular imaging technique currently available for clinical use.
  • Because deranged tumour metabolism is a common finding in many malignancies, PET is frequently used for tissue characterisation, staging and therapy control.
  • A questionnaire comprising 24 items was developed for standardised quality assessment according to evidence-based medicine (EBM) criteria.
  • Clinical indications (grade 1a or 1b) were established for differentiating benign from malignant lesions in pulmonary nodules, pancreatic masses and residual masses after chemotherapy in malignant lymphoma.
  • Staging was improved by FDG-PET in oesophageal cancer, breast cancer, head and neck cancer, lung cancer, malignant lymphoma and malignant melanoma.
  • Effectiveness of radio- and/or chemotherapy could be better controlled in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
  • Restaging was improved in relapsing thyroid cancer, colorectal cancer, head and neck cancer, lung cancer and malignant melanoma.
  • In summary, the efficiency of FDG-PET was studied in several thousand patients with malignant tumours and was found to be well documented in the international high-quality peer-reviewed literature.
  • There are clear-cut clinical indications for FDG-PET in diagnosis, staging and therapy control, and the technique can help to improve the management of many patients with cancer.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702115.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 182
  •  go-up   go-down


38. Galustian C, Dalgleish A: Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother; 2009 Jan;10(1):125-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide: a novel anticancer drug with multiple modalities.
  • Over the past 5 years, lenalidomide (Revlimid, Celgene Co., Summit, NJ, USA), a member of a class of drugs termed immunomodulatory drugs, has emerged as a significant weapon in the arsenal of cancer-therapeutics.
  • It is a lead therapeutic in multiple myeloma and del-5q myelodysplastic syndromes and has also been trialed for acute leukaemia and chronic lymphocytic leukaemia, relapsed or refractory Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, prostate cancer, non-small cell lung cancer, malignant melanoma, renal cancer, advanced ovarian and peritoneal carcinoma.
  • The following review describes key clinical and mechanistic breakthroughs that have made lenalidomide a leading cancer therapeutic.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Thalidomide / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236186.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Number-of-references] 78
  •  go-up   go-down


39. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, Zacher M, Spunt SL, Strickland DK, Hudson MM: Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg; 2003 Nov;38(11):1574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature.
  • METHODS: The authors reviewed the medical records of 8 children with PTM and 17 children with STM referred to St Jude Children's Research Hospital between February 1962 and February 2002 for evaluation and treatment of malignant thyroid carcinoma.
  • Three of the 8 (37.5%) had metastatic disease involving regional lymph nodes; 2 patients (25.0%) had lung metastases.
  • All 8 patients remain alive a median of 22.6 years after diagnosis (range, 0.7 to 30.5 years); 1 continues to receive radioactive iodine (I 131) ablation for persistent disease.
  • Seventeen patients had thyroid carcinoma as a second malignant neoplasm after treatment for acute lymphoblastic leukemia (n = 6), Hodgkin's disease (n = 5), central nervous system tumor (n = 2), Wilms' tumor (n = 1), retinoblastoma (n = 1), non-Hodgkin's lymphoma (n = 1), or neuroblastoma (n = 1).
  • Patients with secondary thyroid carcinoma presented at a median age of 21.5 years (range, 15.3 to 42.6 years), a median of 16.2 years (range, 0.9 to 29.2 years) after diagnosis of the primary cancer.
  • Twelve of the 17 patients (70.6%) had received radiation to the thyroid gland during therapy for the primary cancer.
  • At the time of this report, all 17 patients are alive and in continue to be free of disease.
  • CONCLUSIONS: Pediatric thyroid carcinoma is uncommon and responds well to current therapy.
  • Given the limited period of follow-up of our cohort of secondary malignant thyroid tumors that arise after childhood cancer, these lesions appear to have similar presentations and outcomes when compared with primary carcinomas and can therefore be managed in the same manner.
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasms / drug therapy. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology. Retrospective Studies. Tennessee / epidemiology. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614703.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 49
  •  go-up   go-down


40. Latz D, Nassar N, Frank R: Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie; 2004 Dec;27(6):572-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trofosfamide in the palliative treatment of cancer: a review of the literature.
  • The main indications for application were in the palliative situation and as maintenance therapy.
  • Good results were reported from the treatment of non-Hodgkin's lymphomas and soft tissue sarcomas.
  • A lot of small studies and casuistic contributions are available giving treatment results of several solid carcinomas (malignant gliomas, ovarian, lung and prostate cancer, and others).
  • Due to its oral formulation and good tolerability trofosfamide is an attractive candidate for the palliative situation because treatment on an outpatient basis is possible.
  • Thus, evidence-based conclusions on the therapeutic value of the drug cannot be drawn.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Cyclophosphamide / analogs & derivatives. Cyclophosphamide / therapeutic use. Lymphoma / drug therapy. Palliative Care / methods. Sarcoma / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Neoplasms / drug therapy. Treatment Outcome


41. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E: Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol; 2000 Aug;35(2):75-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxaliplatin (Eloxatin), a recently developed third-generation cisplatin analogue with a 1,2-diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in a wide variety of tumour types.
  • Clinical investigations of single agent and combination therapies in breast, lung, prostate and germ-cell carcinomas, non-Hodgkin's lymphoma and malignant mesothelioma are being pursued.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. DNA Adducts / therapeutic use. Drug Resistance. Female. Humans. Ovarian Neoplasms / drug therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10936465.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  • [Number-of-references] 113
  •  go-up   go-down






Advertisement